Behrad Derakhshan is Chief Business Officer at Edgewise Therapeutics, Inc. (EWTX). They have made 7 open-market trades across 1 company since 2023, most recently 2026-08-12.
CIK 0001853109
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 7 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| EWTX | 31,826 | $1.2M |
Shares reported on the most recent Form 4, priced at the 2026-08-14 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| EWTX | SELL | 2026-08-12 | 2026-08-14 | $43.81 | $223K | +1.7% | +2.0% | — |
| EWTX | SELL | 2025-08-12 | 2025-08-14 | $13.39 | $33K | +4.4% | -2.0% | +51.4% |
| EWTX | SELL | 2025-05-02 | 2025-05-07 | $16.45 | $28K | +1.9% | +5.0% | -5.3% |
| EWTX | SELL | 2025-02-05 | 2025-02-07 | $30.03 | $300K | +2.6% | +4.2% | -44.3% |
| EWTX | SELL | 2024-09-20 | 2024-09-24 | $29.03 | $2.4M | +12.6% | +37.2% | +18.8% |
| EWTX | SELL | 2024-05-02 | 2024-05-03 | $18.91 | $32K | -8.4% | -9.8% | -13.2% |
| EWTX | SELL · 10b5-1 | 2024-02-07 | 2024-02-09 | $20.02 | $200K | -9.9% | -13.1% | +3.8% |
| EWTX | SELL | 2023-05-02 | 2023-05-03 | $8.90 | $16K | -2.1% | +5.3% | -23.5% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.